BI Looks To Afatinib For Global/Asian Leadership In Lung Cancer
This article was originally published in PharmAsia News
Executive Summary
Family-owned German drug firm Boehringer Ingelheim is hoping to combine the superiority of its lung cancer treatment afatinib with new outreach and financing models to gain market leadership in oncology, with Asia seen as an important new market for the product amid growing cancer incidence.